Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 14 de abr de 2024
ID: NCT06312176
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
INTERVENTIONAL
Inicio: 16 de abr de 2019
ID: NCT03875235
Completado
Fase 3
ClinicalTrials.gov
A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes
INTERVENTIONAL
Inicio: 1 de nov de 2001
ID: NCT00312208
Completado
Fase 3
ClinicalTrials.gov
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma
INTERVENTIONAL
Inicio: 13 de dic de 2023
ID: NCT06058793
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
INTERVENTIONAL
Inicio: 1 de may de 2005
ID: NCT00117598
Completado
Fase 2
ClinicalTrials.gov
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
INTERVENTIONAL
Inicio: 19 de dic de 2017
ID: NCT03338790
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
INTERVENTIONAL
Inicio: 18 de dic de 2017
ID: NCT03144674
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
INTERVENTIONAL
Inicio: 6 de may de 2019
ID: NCT03898180
Completado
Fase 2
ClinicalTrials.gov
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
INTERVENTIONAL
Inicio: 6 de dic de 2017
ID: NCT03369223
Completado
Fase 2
ClinicalTrials.gov
Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
INTERVENTIONAL
Inicio: 30 de nov de 2016
ID: NCT02913313
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00662597
Completado
Fase 3
ClinicalTrials.gov
Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822
INTERVENTIONAL
Inicio: 1 de ago de 2005
ID: NCT00721123
Completado
Fase 3
ClinicalTrials.gov
A Randomized Phase II-III Multicenter Trial of Docetaxel Plus Cisplatin and Docetaxel Plus 5-FU Versus Cisplatin Plus 5-FU in 1st Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
INTERVENTIONAL
Inicio: 1 de ene de 1998
ID: NCT00401323
Completado
ClinicalTrials.gov
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
OBSERVATIONAL
Inicio: 1 de sept de 2006
ID: NCT01142674
Terminado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment
INTERVENTIONAL
Inicio: 3 de oct de 2012
ID: NCT01633060
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer.
INTERVENTIONAL
Inicio: 1 de feb de 2007
ID: NCT00439517
Completado
Fase 2
ClinicalTrials.gov
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
INTERVENTIONAL
Inicio: 1 de ene de 2007
ID: NCT00425555
Completado
Fase 2
ClinicalTrials.gov
Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer
INTERVENTIONAL
Inicio: 31 de mar de 2005
ID: NCT00124527
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
INTERVENTIONAL
Inicio: 12 de mar de 2025
ID: NCT06615479
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)
INTERVENTIONAL
Inicio: 25 de jul de 2017
ID: NCT03189719
Anterior
1
...
66
67
68
...
434
Siguiente
Filtros